FGP
TVTX icon

Freestone Grove Partners’s Travere Therapeutics TVTX Stock Holding History

Freestone Grove Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$111K Buy
+3,724
New +$111K ﹤0.01% 796
2025
Q1 		– Sell
-25,521
Closed -$445K – 796
2024
Q4 		$445K Buy
+25,521
New +$451K 0.01% 396

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Freestone Grove Partners's TVTX Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 3,724 shares worth $111K. The stake represents ﹤0.01% of the portfolio and ranks #796 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in TVTX as recently as Q4 2024.

Freestone Grove Partners first reported a position in TVTX in Q4 2024 and has held it in 2 quarters since. The position peaked at $445K in Q4 2024. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Freestone Grove Partners held 3,724 shares of Travere Therapeutics worth $111K as of Q1 2026.
  • Travere Therapeutics was a new Freestone Grove Partners position in Q1 2026.
  • Travere Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #796 holding.
  • Freestone Grove Partners first reported a position in Travere Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • Freestone Grove Partners's Travere Therapeutics position peaked at $445K in Q4 2024.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.